A Phase 2 interventional study of Fluticasone Furoate and Fluticasone Propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 139 sites in 15 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 2, and was the 23rd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 597 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 33rd largest by enrollment of the 238 interventional ones that give a count, is one of 23 that started in 2012, is one of 59 in phase 2, and was the 145th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at the screening visit (Visit 1) will enter a four week run-in period during which time they will continue their current medications. Visit 2 will occur two weeks into the run-in period to allow a review of compliance with daily diary and run-in medication. At Visit 3 (end of run-in/randomization visit), subjects meeting the eligibility criteria who remain uncontrolled despite baseline therapy will be stratified based on pre screening inhaled corticosteroid (ICS) use. Once stratified, subjects will be randomised to the treatment phase of the study where they will receive one of five treatments for 12 weeks. Approx 1200 subjects ages 5 to 11 will be screened to achieve 575 randomized for a total of 115 randomized/evaluable subjects per treatment arm. Subjects will attend on-treatment visits at 2, 4, 8 and 12 weeks (Visits 4, 5, 6 and 7 respectively). A follow-up contact will be performed one week after completing study medication. All subjects must attempt spirometry measurements at Visits 1 and 3. For all subjects, a timed 24-hour urine collection for urinary cortisol and creatinine excretion will be performed prior to randomization at Visit 2 and within 7 days prior to Visit 7. All subjects must perform PEF daily between visits 1 and 7. The primary endpoint will be change from baseline in pre-dose (i.e. dosing trough) PM PEF from patient hand held electronic daily diary at Endpoint (Endpoint is defined as the mean over the last 7 days of treatment). Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry, urinary cortisol, and vital signs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
Drug: Fluticasone Furoate
Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
Drug: Fluticasone Furoate
Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
Drug: Fluticasone Furoate
Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
Drug: Fluticasone Propionate
Placebo inhalation powder once daily in the evening Placebo powder
Drug: Placebo
current asthma medicine
Fluticasone propionate
placebo
Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline AM PEF, actual pre-screening inhaled corticosteroid (ICS) use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.
Time frame: Baseline; Week 1 up to Week 12
Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, actual pre-screening ICS use, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements. Only those participants available at the specified time points were analyzed.
Time frame: Baseline, Week 12
Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period
The number of inhalations of rescue albuterol/salbutamol aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. The Baseline rescue-free value was defined as the percentage of rescue-free 24-hr periods from the last 7 days of the Run-in Period. Change from Baseline was calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment.
Time frame: Baseline; Week 1 up to Week 12
Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period (at Week 12) minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.
Time frame: Baseline; Week 1 up to Week 12
Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in PM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.
Time frame: Baseline; Week 12
Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in AM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.
Time frame: Baseline; Week 12
Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the percentage of symptom free 24-hr periods in the last 7 days of the run-in period. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment group.
Time frame: Baseline; Week 1 up to Week 12
Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period
The number of participants whose primary reason for withdrawal from the study was due to lack of efficacy is presented together with p-values for the treatment comparisons.
Time frame: Up to Week 12
1540 participants were screened, 596 participants were randomized, and 593 participants comprise the Intent to Treat Population which include all participants who received at least one dose of study treatment. Participants were stratified at randomization according to their prior inhaled corticosteroid (ICS) use.
| Milestone | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Started | 119 | 118 | 120 | 118 | 118 |
| Completed | 66 | 94 | 87 | 85 | 89 |
| Not completed | 53 | 24 | 33 | 33 | 29 |
| Withdrew: Adverse event | 1 | 0 | 1 | 2 | 1 |
| Withdrew: Lack of efficacy | 42 | 16 | 23 | 21 | 19 |
| Withdrew: Protocol violation | 1 | 2 | 3 | 1 | 3 |
| Withdrew: Protocol defined stopping criteria | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 1 | 1 |
| Withdrew: Physician decision | 3 | 5 | 2 | 4 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 3 | 4 | 3 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each morning prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. The best of three measurements was recorded. Change from Baseline was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using an analysis of covariance (ANCOVA) model with covariates of Baseline AM PEF, actual pre-screening inhaled corticosteroid (ICS) use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.
| Liters per minute (L/min) | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID | Average of FF 50 µg OD and FF 100 µg OD |
|---|---|---|---|---|---|---|
| Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period | 3.3 ± 2.63 | 21.9 ± 2.66 | 22.8 ± 2.65 | 15.8 ± 2.64 | 17.3 ± 2.64 | 19.3 ± 1.86 |
Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 is defined as a pre-dose FEV1 measurement taken at a clinic visit while still on treatment. Change from Baseline was calculated as the Week 12 trough FEV1 value minus the Baseline value. The Baseline FEV1 value is defined as the value at Visit 3 (randomization). The analysis was performed using an ANCOVA model with covariates of Baseline trough FEV1, region, actual pre-screening ICS use, sex, age, and treatment. The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing measurements. Only those participants available at the specified time points were analyzed.
| Liters | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver | 0.128 ± 0.0264 | 0.254 ± 0.0272 | 0.150 ± 0.0252 | 0.162 ± 0.0272 | 0.192 ± 0.0262 |
The number of inhalations of rescue albuterol/salbutamol aerosol (medication used to relieve symptoms immediately) used during the day and night) was recorded by the participants in a daily diary. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered as rescue free. The Baseline rescue-free value was defined as the percentage of rescue-free 24-hr periods from the last 7 days of the Run-in Period. Change from Baseline was calculated as the average value during the 12-week Treatment Period minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment.
| Percentage of rescue-free 24-hr periods | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period | 16.5 ± 3.01 | 24.9 ± 3.03 | 26.3 ± 3.03 | 28.7 ± 3.02 | 22.7 ± 3.01 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline was calculated as the value of the averaged daily PM PEF over the 12-week Treatment Period (at Week 12) minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. Particpants analyzed included those who have PEF data for at least 2 non-missing days in the Baseline week prior to randomisation and at least 2 non-missing days after randomisation.
| liters per minute (L/min) | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period | 5.1 ± 2.76 | 16.3 ± 2.81 | 18.5 ± 2.77 | 13.5 ± 2.78 | 13.1 ± 2.77 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in PM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, actual pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.
| L/min | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12) | 5.0 ± 3.75 | 16.2 ± 3.80 | 18.2 ± 3.77 | 11.0 ± 3.76 | 11.3 ± 3.75 |
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF was measured by the participants using a hand-held electronic peak flow meter each evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use. Change from Baseline in AM PEF was calculated as the value over the last 7 days of the Treatment Period minus the Baseline value. The Baseline PEF value is defined as the average of the last 7 days of the Run-in Period. Statistical analysis was performed using ANCOVA model with covariates of Baseline, pre-screening ICS use, region, sex, age, and treatment. The LOCF method was used to impute missing data, in which the last non-missing post-Baseline on-treatment measurement was used to impute the missing measurements.
| L/min | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12) | 2.7 ± 3.81 | 23.3 ± 3.85 | 20.6 ± 3.83 | 14.2 ± 3.82 | 19.3 ± 3.82 |
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the PEF measurement. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline symptom-free value is defined as the percentage of symptom free 24-hr periods in the last 7 days of the run-in period. Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value. The analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, actual pre-screening ICS use, age, and treatment group.
| Percentage of symptom-free 24-hr periods | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period | 19.0 ± 2.90 | 21.0 ± 2.92 | 24.7 ± 2.90 | 22.9 ± 2.91 | 22.0 ± 2.91 |
The number of participants whose primary reason for withdrawal from the study was due to lack of efficacy is presented together with p-values for the treatment comparisons.
| Participants | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period | 42 | 16 | 23 | 21 | 19 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the follow-up visit (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/119 (0%) | 20/119 (16.8%) |
| FF 25 µg OD | — | 0/118 (0%) | 27/118 (22.9%) |
| FF 50 µg OD | — | 1/120 (0.8%) | 20/120 (16.7%) |
| FF 100 µg OD | — | 1/118 (0.8%) | 29/118 (24.6%) |
| FP 100 µg BID | — | 0/118 (0%) | 24/118 (20.3%) |
| Event | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| Hepatitis AInfections and infestations | 0/119 | 0/118 | 0/120 | 1/118 | 0/118 |
| SyncopeNervous system disorders | 0/119 | 0/118 | 1/120 | 0/118 | 0/118 |
| Event | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 6/119 | 7/118 | 1/120 | 10/118 | 5/118 |
| NasopharyngitisInfections and infestations | 4/119 | 9/118 | 4/120 | 3/118 | 4/118 |
| HeadacheNervous system disorders | 2/119 | 2/118 | 2/120 | 7/118 | 4/118 |
| PharyngitisInfections and infestations | 4/119 | 2/118 | 7/120 | 5/118 | 1/118 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/119 | 6/118 | 1/120 | 6/118 | 5/118 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/119 | 6/118 | 2/120 | 2/118 | 4/118 |
| Upper respiratory tract infectionInfections and infestations | 3/119 | 1/118 | 0/120 | 4/118 | 3/118 |
| PyrexiaGeneral disorders | 0/119 | 4/118 | 1/120 | 2/118 | 1/118 |
| Body temperature increasedInvestigations | 0/119 | 3/118 | 0/120 | 0/118 | 4/118 |
| BronchitisInfections and infestations | 1/119 | 2/118 | 4/120 | 2/118 | 2/118 |
| Age, Continuous(Years) | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID | Total |
|---|---|---|---|---|---|---|
| Mean | 8.0 ± 1.91 | 7.9 ± 2.08 | 8.4 ± 1.62 | 7.8 ± 2.04 | 7.9 ± 1.87 | 8.0 ± 1.92 |
| Sex: Female, Male(Participants) | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID | Total |
|---|---|---|---|---|---|---|
| Female | 49 | 41 | 46 | 48 | 39 | 223 |
| Male | 70 | 77 | 74 | 70 | 79 | 370 |
| Race/Ethnicity, Customized(Participants) | Placebo | FF 25 µg OD | FF 50 µg OD | FF 100 µg OD | FP 100 µg BID | Total |
|---|---|---|---|---|---|---|
| African American/African Heritage | 4 | 4 | 7 | 8 | 7 | 30 |
| American Indian or Alaskan Native | 24 | 17 | 16 | 17 | 21 | 95 |
| Asian -Central/South Asian Heritage | 1 | 0 | 1 | 0 | 0 | 2 |
| Asian - Japanese Heritage | 7 | 7 | 5 | 2 | 7 | 28 |
| White - Arabic/North African Heritage | 1 | 2 | 0 | 1 | 0 | 4 |
| White - White/Caucasian/European Heritage | 47 | 55 | 51 | 51 | 43 | 247 |
| Mixed Race | 35 | 33 | 40 | 39 | 40 | 187 |
Showing the first 100 of 139 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Mar 2012 to primary completion in Sep 2014, 29 months.
Results were first posted in Apr 2015, 7 months after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 29 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Fluticasone